Anti-Chlamydial LPS Antibody, clone EVI-H1 clone EVI-H1, from mouse

Chlamydia trachomatis is a Gram-negative bacterium that is responsible to sexually transmitted diseases leading to pelvic inflammatory disease, ectopic pregnancy, infertility, and outbreaks of trachoma-associated blindness and lymphogranuloma venereum (LGV). Chlamydia trachomatis consists of eighteen different serological variants (serovars) that include a few subvariants. These are identified based on serological reactivity of the epitopes on their outer membrane. Intracellularly chlamydia replicates within a vacuole. Chlamydia infection is initiated with the expression of a chlamydial early gene product(s), which isolate the inclusion from the endocytic-lysosomal pathway and makes it fusogenic with sphingomyelin-containing exocytic vesicles. This change in vesicular interaction allows the delivery of the vacuole to the peri-Golgi region of the host cell. Antigens from all members of the Chlamydia genus display heat resistance and sensitivity to oxidation by sodium periodate. Lipopolysaccharides (LPS) of Chlamydia consists of at least three antigen domains, two of which are shared by the LPS of certain other gram-negative organisms and one that is unique only to chlamydial LPS. It has been reported that the quantitative yields of chlamydial LPS can be achieved when elementary bodies (EBs) are first reduced and alkylated prior to extraction with hot phenol-water. (Ref.: Caldwell, HD., and Hitchcock, PJ. (1984). Infect. Immun. (44(2); 306-314; Scidmore, MA., et al. (1996). Infect. Immun. 64(12); 5366-5372; Turingan, RS et al. (2017). PLoS ONE 12(5): e0178653).